Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer's Drug
10:49am, Tuesday, 11'th Jun 2024
Eli Lilly (NYSE: LLY ) stock is continuing a recent rally over the last year as a Food and Drug Administration (FDA) panel signs off on its Alzheimer's drug. The FDA panel voted unanimously in favor o
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
10:30am, Tuesday, 11'th Jun 2024
Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.
FDA Nudge Sends Pharma Stock to Fresh Record Highs
10:00am, Tuesday, 11'th Jun 2024
Shares of Eli Lilly And Co (NYSE:LLY) are enjoying a 2.3% surge this morning, last seen trading near $885.10 on the back of news that the Food and Drug Administration (FDA) panel unanimously approved
Top 4 Health Care Stocks That May Keep You Up At Night This Month
08:44am, Tuesday, 11'th Jun 2024
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first time
08:15am, Tuesday, 11'th Jun 2024
Dr. Howard Fillit, Alzheimer's Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the
Morning Minute: Tuesday, June 11
08:05am, Tuesday, 11'th Jun 2024
Apple (AAPL) announces new A.I. initiatives, Eli Lilly (LLY) stock is on the move after its Alzheimer's drug gets positive news and Alphabet (GOOGL) receives positive analyst notes.
Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?
05:50am, Tuesday, 11'th Jun 2024
Lilly's current product lineup includes multiple growth drivers, including Mounjaro and Zepbound. The company's pipeline also features promising candidates, with two currently awaiting regulatory appr
Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab
10:20pm, Monday, 10'th Jun 2024
Eli Lilly (LLY) shares gained more than 2% in extended trading on Monday after a panel of independent advisors to the Food and Drug Administration (FDA) unanimously recommended the pharmaceutical gian
2 Biotech Stocks For Your June 2024 Watchlist
08:52pm, Monday, 10'th Jun 2024
Biotech stocks to check out in the stock market now.
Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference
08:20pm, Monday, 10'th Jun 2024
Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 4:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President of Lilly Dia
FDA Panel Unanimously Recommends Eli Lilly's Alzheimer's Drug
07:15pm, Monday, 10'th Jun 2024
A Food and Drug Administration advisory panel unanimously voted Monday to recommend Eli Lilly's Alzheimer's drug donanemab for approval, according to multiple outlets, sending the pharmaceutical compa
Apple Joins A.I. Race; Lilly Thumbs-Up on Alzheimer's Drug
06:26pm, Monday, 10'th Jun 2024
Considering how many Apple products there are out there in the world at this time, a high number of them will soon be accessing A.I. from an Apple device.
FDA advisers say Eli Lilly Alzheimer's treatment is effective
06:23pm, Monday, 10'th Jun 2024
Dr. Scott Gottlieb, Former FDA Commissioner, joins 'Closing Bell Overtime' to talk news that the FDA has deemed Eli Lilly's Alzheimers treatment as effective.
Eli Lilly exec expects obesity pill data in April 2025
05:30pm, Monday, 10'th Jun 2024
Data from Eli Lilly's late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly executive said on Monday.
Eli Lilly's Alzheimer's drug gets backing from FDA advisers
04:37pm, Monday, 10'th Jun 2024
Eli Lilly & Co.'s experimental Alzheimer's drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug Adminis
